#Switzerland #Basel #CordenPharma #Dr. Jean-Luc #Dr. Michael Quirmbach

CordenPharma Welcomes Dr. Jean-Luc Herbeaux as New CEO

CordenPharma, a leading contract development and manufacturing organization (CDMO) in the pharmaceutical sector, has recently proclaimed the appointment of Dr. Jean-Luc Herbeaux as its new Chief Executive Officer, effective from October 1, 2026. This leadership change signifies an important milestone in the company’s ongoing growth journey. Dr. Herbeaux takes the reins from Dr. Michael Quirmbach, the former CEO, who will now transition to a Board Member and Senior Advisor role after a remarkable 12-year tenure.

Transitioning Leadership

Dr. Quirmbach has been pivotal in steering CordenPharma since 2019, guiding the company through an expansive growth period that has seen annual revenue increase from €245 million to over €1 billion. Throughout his time, he has successfully executed a focused strategy that integrated operations and expanded the company's global footprint across Europe, the U.S., and Asia.

As part of the planned leadership transition, Dr. Quirmbach will maintain an active role within CordenPharma, bringing his extensive experience and industry knowledge as he supports Dr. Herbeaux in the company's future endeavors.

Background of Dr. Jean-Luc Herbeaux

Before joining CordenPharma, Dr. Herbeaux served as the CEO of Hovione, another prominent CDMO, for over four years. His previous roles included Chief Operating Officer there and several senior positions at Evonik, a global leader in specialty chemicals and materials. With such a rich background in operations and leadership within the pharmaceutical manufacturing space, Dr. Herbeaux is well-positioned to lead CordenPharma in its next chapter.

In his new role, he aims to drive the execution of the company's long-term strategy while continuing to enhance customer satisfaction and operational execution. His leadership comes at a vital time as CordenPharma has recently expanded its manufacturing capabilities, including the acquisition of peptide CDMO AmbioPharm.

Looking Toward the Future

Dr. Herbeaux expressed enthusiasm for the opportunity, stating, "I am excited to join CordenPharma and work alongside Astorg at a defining stage of the company's development. I have great respect for what Michael and the team have built and see significant opportunities ahead." He emphasizes the need to execute growth plans with clarity and deepening partnership relations.

CordenPharma's success as a CDMO caters to a multitude of customers, supporting early development through to commercial manufacturing, reflecting the company’s commitment to enhancing healthcare outcomes through innovative drug development.

The Company’s Path Ahead

With approximately 3,500 employees and a broad international network of facilities, CordenPharma is poised for continued advancements. The leadership transition, along with strategic investments and acquisitions, positions the organization favorably within the highly competitive pharmaceutical landscape.

As CordenPharma embarks on this new phase, both Dr. Quirmbach and Dr. Herbeaux affirm a dedication to collaboration, innovation, and driving significant contributions to the healthcare sector. Under their guidance, CordenPharma is eager to continue providing high-value services that support the global biopharmaceutical industry.

For more insights about CordenPharma, you can visit their official website and follow their endeavors and updates on LinkedIn.